Gilead Announces Sustained Virologic Response Rate for Sofosbuvir
Gilead Sciences today announced topline results from the Phase 3 POSITRON study examining a 12-week course of once-daily sofosbuvir plus ribavirin ( RBV ) in patients with genotype 2 or 3 chronic hepatitis C virus ( HCV ) infection who are not candidates to take interferon ( IFN ).
FDA approves new indication for Promacta
GlaxoSmithKline announced today that the US Food and Drug Administration (FDA) has approved PROMACTA ® for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.
Cancer's Tipping Point Of No Return
Hepatitis B infection is serious business. The virus attacks and damages the liver which, over time, can lead to liver cancer.
Get Your Measles Booster With The Milk
Getting your flu shot — and nine other common vaccines — just became a bit more convenient. No need to hassle with a doctor appointment. Just drop by Walmart.
Know Your Risk: Hepatitis C and HIV
You may not know if you've been infected with hepatitis C. It's earned the nickname “the silent epidemic” by hiding its symptoms until it's caused significant damage to your liver.
Ten Years of Hepatitis A Protection
While some vaccines can be given once and offer protection for life, others require booster shots and still may wear off over time.
New Antidepressant for Hep C
Pegylated interferon-a drugs used to manage hepatitis C can cause major depression. Preventative use of the antidepressant, escitalopram or Lexapro, may be the solution for some patients.
HIV and HBV: Partners in Crime
If you have HIV, one of the most dangerous risks is becoming infected with another chronic disease at the same time. Hepatitis B is one of HIV's most common infectious partners.
Baby Boomers: Get Tested for Hep C
Are you a member of the baby boomer generation? Next time you go to the doctor, they may recommend getting tested for hepatitis C.
Liver Cancer's Inheritance
The link between viruses that cause hepatitis and the development of cancer is believed to be why several areas in Asia have higher rates of liver cancer. New research indicates that may not be the full story.